Oragenics, Inc. announced that, on February 12, 2024, the Company and Kimberly Murphy, the Company?s Chief Executive Officer, entered into a mutually agreeable Separation Agreement (the ?Separation Agreement?), pursuant to which Ms. Murphy?s employment with the Company terminated effective February 12, 2024. Ms. Murphy will, however, continue to serve the Company as a member of the Company?s board of directors (the ?Board?). Ms. Murphy?s resignation as an officer was not due to any disagreement with the Company on any matter related to its operations, policies or practices.

In addition, effective February 12, 2024, the Board appointed Michael Redmond, the Company?s President, as the Company?s Interim Principal Executive Officer.